7-hydroxymitragynine (often shortened to 7-OH) is a potent opioid-active compound found in kratom, the leaves of the Southeast Asian tree Mitragyna speciosa. It binds to the same brain receptors as morphine, though morphine still has roughly 8 to 10 times greater binding affinity. What makes 7-OH notable is that it’s far more potent than mitragynine, the most abundant alkaloid in kratom, with 5 to 23 times stronger receptor binding. It has become the subject of growing concern as concentrated 7-OH products have appeared in smoke shops and online retailers.
Where 7-OH Comes From
7-hydroxymitragynine is not typically present in fresh kratom leaves. It forms during the drying and processing of the leaf material, and it also forms inside your body. When you consume kratom, the liver enzyme CYP3A converts mitragynine into 7-hydroxymitragynine as a metabolic byproduct. So even if a kratom product contains little 7-OH on its own, your body will produce some after ingestion.
This matters because the commercial landscape has shifted. Rather than relying on the small amounts generated naturally through drying or metabolism, some manufacturers now sell isolated or concentrated 7-OH in tablets, gummies, and liquid shots. These products deliver the compound directly and at much higher levels than traditional kratom leaf ever would.
How It Works in the Body
7-OH acts as a partial agonist at the mu-opioid receptor, the same receptor targeted by morphine, heroin, and prescription painkillers. “Partial agonist” means it activates the receptor but not to its full capacity. At the mu-opioid receptor, 7-OH reaches about 41% of the maximum possible activation, compared to what a full agonist like morphine achieves. This partial activation produces pain relief and sedation while, in theory, placing a ceiling on certain dangerous effects.
Interestingly, mitragynine itself acts as an antagonist (a blocker) at the same receptor, while 7-OH does the opposite by activating it. This distinction is a key reason researchers treat the two compounds as pharmacologically very different, even though one converts into the other. 7-OH also binds preferentially to mu-opioid receptors over the other two opioid receptor types (kappa and delta), with a binding affinity of about 78 nanomolar, roughly 100 times stronger than mitragynine’s.
Potency Compared to Morphine
A World Health Organization review found that 7-OH has 5 to 20 times more receptor activation than mitragynine. Morphine, however, still outpaces 7-OH, with about 3 times more intrinsic activity and 8 to 10 times greater binding affinity. So 7-OH sits in a middle zone: considerably stronger than the main alkaloid in kratom leaf, but weaker than morphine on a molecule-to-molecule basis.
That comparison can be misleading, though, because the concentrated 7-OH products now on the market aren’t constrained by the low natural levels found in dried leaf. A tablet or shot delivering milligrams of pure 7-OH is a fundamentally different exposure than brewing kratom tea.
How Long It Lasts
After oral consumption, 7-OH reaches peak blood levels in roughly 1 to 1.8 hours. Its elimination half-life (the time for blood levels to drop by half) varies with dose, ranging from about 1.7 hours at lower doses to nearly 6 hours at higher ones. In practical terms, effects begin within an hour, peak shortly after, and taper over the following several hours. Higher doses linger longer because the body takes more time to clear larger amounts.
Respiratory Depression and the Ceiling Effect
One of the central safety questions around 7-OH is whether its partial agonist profile protects against respiratory depression, the main way opioids kill. Animal research has shown mixed results. In mice, mitragynine showed a ceiling effect on breathing suppression, meaning that past a certain dose, breathing didn’t slow down further. 7-OH did not show this ceiling. Instead, it produced dose-dependent respiratory depression: higher doses meant progressively more suppressed breathing, similar to morphine.
At typical low exposures, the partial agonist mechanism does appear to limit respiratory risk compared to full agonists. But at high doses or with repeated use, 7-OH can still produce the full range of opioid toxicity, including dangerous breathing suppression. This is an important distinction for anyone assuming that “partial agonist” automatically means “safe.”
Reported Side Effects
The FDA has received reports of serious adverse effects from 7-OH products, including:
- Addiction and withdrawal symptoms such as restlessness, body aches, fatigue, irritability, and cold sweats
- Psychiatric effects including anxiety, depression, and insomnia
- Gastrointestinal distress such as nausea, vomiting, or stomach pain
- Seizures
The withdrawal profile closely resembles opioid withdrawal, which makes sense given the compound’s mechanism. People who use concentrated 7-OH products regularly can develop physical dependence, and stopping abruptly may trigger classic opioid withdrawal symptoms within hours to days.
Drug Testing
Standard 5-panel and 10-panel drug tests do not screen for kratom alkaloids, including 7-OH. It will not trigger a false positive for other opioids on routine panels. However, specialized laboratory tests using liquid chromatography or mass spectrometry can identify 7-hydroxymitragynine in urine or blood when specifically requested. Some extended panels used by certain employers, courts, or treatment programs now include kratom alkaloids, so detection is possible if someone is looking for it.
Why Concentrated 7-OH Products Raise Concerns
Traditional kratom use involves consuming dried leaf material, which contains mostly mitragynine and only trace amounts of 7-OH formed during drying. The body then converts a small fraction of that mitragynine into 7-OH through liver metabolism. This route produces relatively low and self-limiting blood levels of the active compound.
Isolated 7-OH products bypass that natural bottleneck entirely. They deliver the potent opioid-active metabolite directly, at doses that the body would never produce on its own from whole-leaf kratom. The FDA has stated that exposure to 7-OH “could result in serious harm,” and the agency has specifically warned consumers about these concentrated products. The gap between chewing kratom leaves and swallowing a 7-OH tablet is, pharmacologically, enormous.